Here is a message I posted to someone asking me pm my opinion on future price possible hitting $5 if both mono and cancer were successful. They mentioned to me bluebird bio's market cap.

Quote:

---

At the very least, I would say buyout offer $5 to $10 early. If they get method of action with all ccr5+ cancers, the market cap number is too crazy to contemplate. Gilead has 22B in sales last year. Has 1.3B O/S and 83.6B market cap, $66 dollar share price. If leronlimab could hit 11B yearly sales with half their O/S, that gives the same $66 dollar per share. The potential is $100+ share price. Again, I think BP would step in with such a low market cap now and give a buyout offer cheap ($5-$10) before those sales happen.

---